ROIV Roivant Sciences Ltd.

NASDAQ
$35.80

Roivant Sciences Ltd. (ROIV) Insider Activity

What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.

30D 90D 6M 1Y
Insider signal In line Selling ran in line with ROIV's own trailing one-year pace, with 5% of sale value under a prearranged plan.
Cluster activity 0 buyers in the last 30 days 0 buyers in the last 90 days 7 sellers in the last 90 days
Insiders buying
0
0 transactions
Insiders selling
12
119 transactions
Purchases
$0
0 shares
Sales
$897.0M
35,368,084 shares
Net activity
-$897.0M
purchases less sales

How much of that selling was preplanned? 5% planned / 95% discretionary

10b5-1 plan sales $43.9M 17 transactions · 2,272,259 shares
Discretionary sales $853.2M 102 transactions · 33,095,825 shares

Largest single sale: $43.4M.

Where they traded

Buy Sell Dot area is proportional to transaction value.

Last open-market purchase: September 18, 2025 — 1.0 years ago, by Gline Matthew .

Recent open-market activity

Date Insider Role Action Shares Price Value Held after
Fitzgerald Meghan 2 fills Director Sell 10b5-1 5,112 $39.74 $203.2K 36,508 −12.3% of holding
Epperly Melissa B, 2 fills Director Sell 10b5-1 4,938 $39.74 $196.2K 10,500 −32% of holding
Fitzgerald Meghan Director Sell 10b5-1 20,000 $39.90 $798.0K 42,963 −31.8% of holding
Venker Eric 2 fills President & Immunovant CEO Sell 10b5-1 200,000 $35.77 $7.2M 1,632,972 −10.9% of holding
Sukhatme Mayukh President & CIO Sell 144,756 $36.48 $5.3M 18,630,739 −0.8% of holding
Sukhatme Mayukh President & CIO Sell 17,519 $37.30 $653.5K 18,630,739 −0.1% of holding
Sukhatme Mayukh President & CIO Sell 172,899 $37.17 $6.4M 18,630,739 −0.9% of holding
Sukhatme Mayukh 2 fills President & CIO Sell 136,942 $36.73 $5.0M 18,630,739 −0.7% of holding
Sukhatme Mayukh President & CIO Sell 284,707 $36.25 $10.3M 18,630,739 −1.5% of holding
Sukhatme Mayukh President & CIO Sell 243,177 $36.23 $8.8M 18,630,739 −1.3% of holding
Venker Eric President & Immunovant CEO Sell 200,000 $34.95 $7.0M 1,613,063 −11% of holding
MANCHESTER KEITH S 2 fills Director Sell 212,380 $35.44 $7.5M 13,689,166 −1.5% of holding
QVT Financial LP Other Sell 12,380 $35.28 $436.8K 13,689,166 −0.1% of holding
Gold Daniel Allen Director Sell 12,380 $35.28 $436.8K 13,689,166 −0.1% of holding
Fitzgerald Meghan Director Sell 10,000 $34.90 $349.0K 42,963 −18.9% of holding
MANCHESTER KEITH S 2 fills Director Sell 800,000 $34.55 $27.6M 14,301,546 −5.3% of holding
QVT Financial LP 2 fills Other Sell 800,000 $34.55 $27.6M 14,301,546 −5.3% of holding
Gold Daniel Allen 2 fills Director Sell 800,000 $34.55 $27.6M 14,301,546 −5.3% of holding
Epperly Melissa B, 2 fills Director Sell 17,750 $34.38 $610.3K 19,222 −48% of holding
Gold Daniel Allen 2 fills Director Sell 625,783 $34.00 $21.3M 14,826,546 −4% of holding
MANCHESTER KEITH S 2 fills Director Sell 625,783 $34.00 $21.3M 14,826,546 −4% of holding
QVT Financial LP 2 fills Other Sell 625,783 $34.00 $21.3M 14,826,546 −4% of holding
Sukhatme Mayukh President & CIO Sell 500,000 $34.08 $17.0M 18,677,617 −2.6% of holding
Sukhatme Mayukh President & CIO Sell 500,000 $34.13 $17.1M 18,677,617 −2.6% of holding
Venker Eric 2 fills President & Immunovant CEO Sell 200,000 $33.16 $6.6M 1,659,297 −10.8% of holding
Venker Eric President & Immunovant CEO Sell 200,000 $30.27 $6.1M 1,613,063 −11% of holding
Venker Eric President & Immunovant CEO Sell 200,000 $29.59 $5.9M 1,647,546 −10.8% of holding
Gline Matthew CEO Sell 289,774 $29.16 $8.4M 16,736,116 −1.7% of holding
Humes Jennifer Chief Accounting Officer Sell 13,538 $28.37 $384.1K 84,191 −13.9% of holding
Fitzgerald Meghan Director Sell 70,000 $27.45 $1.9M 42,963 −62% of holding
Venker Eric President & Immunovant CEO Sell 200,000 $28.24 $5.6M 1,647,546 −10.8% of holding
Epperly Melissa B, Director Sell 41,861 $28.68 $1.2M 15,804 −72.6% of holding
Torti Frank President and Vant Chair Sell 587,390 $27.51 $16.2M 13,736,547 −4.1% of holding
Torti Frank President and Vant Chair Sell 1,012,610 $27.15 $27.5M 13,736,547 −6.9% of holding
Torti Frank President and Vant Chair Sell 1,400,000 $27.42 $38.4M 13,736,547 −9.2% of holding
Gold Daniel Allen 2 fills Director Sell 375,784 $26.50 $10.0M 15,352,329 −2.4% of holding
MANCHESTER KEITH S 2 fills Director Sell 375,784 $26.50 $10.0M 15,352,329 −2.4% of holding
QVT Financial LP 2 fills Other Sell 375,784 $26.50 $10.0M 15,352,329 −2.4% of holding
Venker Eric President & Immunovant CEO Sell 200,000 $26.49 $5.3M 1,654,597 −10.8% of holding
MANCHESTER KEITH S 2 fills Director Sell 425,000 $26.75 $11.4M 15,778,113 −2.6% of holding
QVT Financial LP 2 fills Other Sell 425,000 $26.75 $11.4M 15,778,113 −2.6% of holding
Gold Daniel Allen 2 fills Director Sell 425,000 $26.75 $11.4M 15,778,113 −2.6% of holding
MANCHESTER KEITH S Director Sell 425,000 $26.67 $11.3M 15,928,113 −2.6% of holding
QVT Financial LP Other Sell 425,000 $26.67 $11.3M 15,928,113 −2.6% of holding
Gold Daniel Allen Director Sell 425,000 $26.67 $11.3M 15,928,113 −2.6% of holding
Sukhatme Mayukh President & CIO Sell 339,441 $26.47 $9.0M 19,148,664 −1.7% of holding
Venker Eric President & Immunovant CEO Sell 200,000 $21.92 $4.4M 1,654,597 −10.8% of holding
Sukhatme Mayukh President & CIO Sell 1,018,995 $21.71 $22.1M 20,267,429 −4.8% of holding
Sukhatme Mayukh President & CIO Sell 311,873 $21.74 $6.8M 19,273,032 −1.6% of holding
Venker Eric President & Immunovant CEO Sell 75,000 $22.53 $1.7M 1,654,597 −4.3% of holding
Pulik Richard 2 fills CFO Sell 406,731 $22.43 $9.1M 386,144 −51.3% of holding
Venker Eric President & Immunovant CEO Sell 200,000 $22.45 $4.5M 1,611,749 −11% of holding
MANCHESTER KEITH S 3 fills Director Sell 777,332 $23.07 $17.9M 16,697,727 −4.4% of holding
QVT Financial LP 3 fills Other Sell 777,332 $23.07 $17.9M 16,697,727 −4.4% of holding
Gold Daniel Allen 3 fills Director Sell 777,332 $23.07 $17.9M 16,697,727 −4.4% of holding
Sukhatme Mayukh President & CIO Sell 26,831 $23.09 $619.5K 18,869,229 −0.1% of holding
MANCHESTER KEITH S 2 fills Director Sell 917,282 $23.04 $21.1M 17,772,727 −4.9% of holding
QVT Financial LP 2 fills Other Sell 917,282 $23.04 $21.1M 17,772,727 −4.9% of holding
Gold Daniel Allen 2 fills Director Sell 917,282 $23.04 $21.1M 17,772,727 −4.9% of holding
Gline Matthew 3 fills CEO Sell 1,740,000 $21.68 $37.7M 18,616,406 −8.5% of holding
Ramaswamy Vivek 10% Owner Sell 353,745 $22.05 $7.8M 34,132,463 −1% of holding
Ramaswamy Vivek 10% Owner Sell 1,975,858 $21.96 $43.4M 36,350,621 −5.2% of holding
Ramaswamy Vivek 10% Owner Sell 774,142 $21.64 $16.8M 34,749,305 −2.2% of holding
Venker Eric President & Immunovant CEO Sell 10b5-1 200,000 $20.85 $4.2M 1,497,908 −11.8% of holding
MANCHESTER KEITH S 4 fills Director Sell 1,300,000 $20.23 $26.3M 18,497,727 −6.6% of holding
QVT Financial LP 4 fills Other Sell 1,300,000 $20.23 $26.3M 18,497,727 −6.6% of holding
Gold Daniel Allen 4 fills Director Sell 1,300,000 $20.23 $26.3M 18,497,727 −6.6% of holding
Ramaswamy Vivek 10% Owner Sell 539,650 $20.51 $11.1M 33,653,756 −1.6% of holding
Ramaswamy Vivek 10% Owner Sell 1,027,670 $20.33 $20.9M 34,193,406 −2.9% of holding
Ramaswamy Vivek 10% Owner Sell 287,283 $20.81 $6.0M 35,221,076 −0.8% of holding
Venker Eric President & Immunovant CEO Sell 10b5-1 200,000 $20.22 $4.0M 1,504,959 −11.7% of holding
Venker Eric President & Immunovant CEO Sell 10b5-1 118,418 $17.06 $2.0M 1,504,959 −7.3% of holding
Venker Eric President & Immunovant CEO Sell 10b5-1 318,282 $17.05 $5.4M 1,504,959 −17.5% of holding
Venker Eric President & Immunovant CEO Sell 10b5-1 414,683 $16.93 $7.0M 1,504,959 −21.6% of holding
Venker Eric President & Immunovant CEO Sell 10b5-1 20,727 $16.25 $336.8K 1,504,959 −1.4% of holding
Venker Eric President & Immunovant CEO Sell 10b5-1 104,940 $16.30 $1.7M 1,504,959 −6.5% of holding
Venker Eric President & Immunovant CEO Sell 10b5-1 138,602 $16.20 $2.2M 1,504,959 −8.4% of holding
Venker Eric President & Immunovant CEO Sell 10b5-1 355,161 $16.15 $5.7M 1,504,959 −19.1% of holding
Venker Eric President & Immunovant CEO Sell 10b5-1 171,396 $16.34 $2.8M 1,504,959 −10.2% of holding

Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.